Mankind Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 23 January 2025.

Powered by Capital Market - Live News

Mankind Pharma has allotted 1,19,04,761 equity shares of face value of Re 1 each to the eligible Qualified Institutional Buyers at the issue price of Rs 2,520/- per equity share, i.e. at a premium of Rs 2519/- per equity share aggregating to Rs 2999.99 crore pursuant to the QIP issue.

Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from Rs 40,06,62,138 consisting 40,06,62,138 equity shares to Rs 41,25,66,899 consisting 412566899 equity shares having face value of Re. 1/- each.

Powered by Capital Market - Live News

The company has approved the allocation of 1,19,04,761 equity shares at an issue price of Rs 2,520 per equity share to the eligible qualified institutional buyers. The issue price represents a discount of 3.69% to the floor price of Rs 2616.55 per equity share.

The company has raised an aggregate sum of Rs 2,999.99 crore from the said issue. Consequent to the aforesaid allotment, the paid-up share capital of the company has increased from Rs 40.06 crore consisting 40.06 crore equity shares to Rs 41.25 crore consisting 41.25 crore equity shares having face value of Re 1 each.

The QIP attracted significant interest from various institutional investors, including SBI Mutual Fund, Government Pension Fund Global, HDFC Trustee Company, Motilal Oswal Midcap Fund, Government of Singapore, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund, NPS Trust, and Aditya Birla Sun Life Trustee.

Mankind pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products.

The company’s consolidated net profit surged 30.43% to Rs 653.47 crore on a 13.6% rise in revenue to Rs 3,076.51 crore in Q2 FY25 as compared to Q2 FY24.

The scrip shed 0.98% to currently trade at Rs 2861.05 on the BSE.

Powered by Capital Market - Live News

The company's board authorized and declared the opening of the issue on Monday, 16 December 2024.

The floor price of Rs 2,616.55 is at a discount of 2.76% to the scrip’s previous closing price of Rs 2,690.80 on the BSE. The company expects to raise a sum of Rs 3,000 crore from the said issue.

The company may offer a discount of not more than 5% on the floor price so calculated for the issue. The issue price will be determined in consultation with the book running lead manager appointed for the issue.

Mankind Pharma intends to use the issue from the proceeds for repayment / pre-payment of certain outstanding borrowings by the company; and for general corporate purposes.

Mankind pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products.

The company’s consolidated net profit surged 30.43% to Rs 653.47 crore on a 13.6% rise in revenue to Rs 3,076.51 crore in Q2 FY25 as compared to Q2 FY24.

Powered by Capital Market - Live News